A Phase I, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and a Tablet Formulation of Enzalutamide Following Multiple Once Daily Doses of 160 mg Enzalutamide in Male Subjects With Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2014
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 12 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Oct 2013 Planned end date changed from 1 Sep 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 09 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.